Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MAZE
MAZE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MAZE News
Maze Therapeutics CEO Jason Coloma Sells $847,000 in Shares Amid Stock Fluctuations
4h ago
NASDAQ.COM
Maze Therapeutics CEO Sells 32,564 Shares
5h ago
Fool
Maze Therapeutics CEO Sells Over 30,000 Shares: Implications for Investors
5h ago
Yahoo Finance
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge
May 17 2026
Fool
Maze Therapeutics Q1 Earnings Beat Expectations
May 12 2026
seekingalpha
Maze Therapeutics Executive Stock Transaction Overview
May 07 2026
Fool
Maze Therapeutics Prices $150M Stock Offering
Apr 22 2026
seekingalpha
Maze Therapeutics Raises $150 Million in Stock Offering
Apr 22 2026
NASDAQ.COM
Maze Therapeutics Prices 5.54 Million Share Offering at $23.50 Each
Apr 22 2026
Newsfilter
Maze Therapeutics Executive Sells Shares Amid Declining Stock Price
Apr 05 2026
Fool
Chief Medical Officer Sells All Shares
Apr 05 2026
NASDAQ.COM
Biotech Landscape Update: Regulatory Approvals and Mergers
Mar 27 2026
NASDAQ.COM
Investigation into Potential Claims for Maze Therapeutics Investors
Mar 26 2026
Globenewswire
Maze Therapeutics Executive Exercises Stock Options Amid Market Volatility
Mar 25 2026
Fool
Maze Therapeutics Shares Plunge 37% Despite Positive Trial Data
Mar 25 2026
seekingalpha
Maze Therapeutics Reports Positive Phase 2 Data for MZE829 in Kidney Disease
Mar 25 2026
NASDAQ.COM
Show More News
